Benzinga | Apr 26, 2021 08:09AM EDT

Immunome's Stock Jumps On Its Antibody Cocktail Neutralizing Multiple COVID-19 Variants In Animal Studies

* Immunome Inc (NASDAQ: IMNM) has announced antibody selection for its IMM-BCP-01 antibody cocktail and shared preclinical data showing that IMM-BCP-01 is effective against the current SARS-CoV-2 and its variants.

* In Syrian hamsters infected with live SARS-CoV-2 virus, IMM-BCP-01 reduced lung viral load as a treatment and prophylaxis.

* Data also demonstrated full neutralization by IMM-BCP-01 of emerging/concerning variants of COVID-19 and mutations.

* Mechanistic studies demonstrate that the selected antibodies bind not only to SARS-CoV-2 spike proteins with complex mutations but also to those with several individual mutations.

* Two of the three selected antibodies bind to areas of the Spike protein that may be resistant to evolutionary change.

* Immunome anticipates filing an IND for its IMM-BCP-001 program in late Q2/early Q3 2021.

* IMM-BCP-01 contains three monoclonal antibodies that bind to non-overlapping regions of the spike protein with picomolar affinity.

* Price Action: IMNM shares are trading 12.7% higher at $33.29 in the premarket session on the last check Monday.